1
|
Ogura H, Yoshizawa N, Ueda S, Hosokawa Y, Matsunuma R, Tochikubo J, Nasu H, Shigekawa T, Takeuchi H, Osaki A, Saeki T, Yoshimoto K, Ohmae E, Suzuki T, Ueda Y, Yamashita Y, Sakahara H. Abstract P4-03-06: Near-infrared diffuse optical imaging for early prediction to neoadjuvant chemotherapy in patients with primary breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-03-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Diffuse optical spectroscopic imaging (DOSI) can be exploited as a marker of tumor blood volume quantified by tissue hemoglobin (tHb) concentration. In DOSI, frequent measurement is possible for breast cancer patients because of its non-invasiveness. The tHb concentration determined by DOSI is expected to be a new biomarker for prediction of breast cancer response to neoadjuvant chemotherapy (NAC).
Purpose: Our objective is to determine whether early change of tumor tHb concentration predicts pathological complete response (pCR) to NAC in patients with operable breast cancer.
Methods: In a prospective study, one hundred patients with primary breast cancer were enrolled for primary objective analysis. The regimens of NAC were according to the standard of care. Patients underwent sequential scans using DOSI at baseline, after 1st course and 2nd course of chemotherapy. The mean value of tHb (tHbmean) concentration of the targeted lesion was measured and the percentage change in tHbmean (ΔtHbmean) concentration was calculated. Receiver operating curve analysis demonstrated diagnostic performance of DOSI for predicting a pCR.
Results: In interim analysis, it was regarded as a good outcome that area under the curve (AUC) for ΔtHbmean after 1nd course was 0.797 (SE 0.104, 95%CI 0.633-0.911), and after 2st course was 0.867 (SE 0.06, 95%CI 0.715-0.956).
Conclusion: DOSI could predict accurately a pCR to neoadjuvant chemotherapy in patients with primary breast cancer.
Citation Format: Ogura H, Yoshizawa N, Ueda S, Hosokawa Y, Matsunuma R, Tochikubo J, Nasu H, Shigekawa T, Takeuchi H, Osaki A, Saeki T, Yoshimoto K, Ohmae E, Suzuki T, Ueda Y, Yamashita Y, Sakahara H. Near-infrared diffuse optical imaging for early prediction to neoadjuvant chemotherapy in patients with primary breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-03-06.
Collapse
Affiliation(s)
- H Ogura
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - N Yoshizawa
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - S Ueda
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Hosokawa
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - R Matsunuma
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - J Tochikubo
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Nasu
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Shigekawa
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Takeuchi
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - A Osaki
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Saeki
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - K Yoshimoto
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - E Ohmae
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Suzuki
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Ueda
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Yamashita
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Sakahara
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| |
Collapse
|
3
|
Ogura H, Yamashita D, Nasu H, Teruya C, Ohmae E, Yoshimoto K, Suzuki T, Ueda Y, Oda M, Yamashita Y, Sakahara H. Abstract P2-05-02: Optical Parameters of Breast Cancer before and after Chemotherapy. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: To analyze optical parameters of cancer before and after chemotherapy in breast cancer patients.Patients and Methods: Absorption coefficient (µa) and reduced scattering coefficient (µs') of cancer and contra-lateral normal region before and after chemotherapy were measured by using TRS-20SH (Hamamatsu Photonics K.K.). A pulsed laser of 760, 800, and 830 nm wave-length was irradiated at multiple sites in both breasts with time-resolved spectroscopy method and scattered light was analyzed by photon diffusion equation. A total of ten breast cancer patients who underwent neoadjuvant chemotherapy participated in the trial. Written informed consent was obtained from all of the patients.Results: Absorption coefficient (µa, 1/cm) of breast cancer was significantly higher than that of contra-lateral normal region before chemotherapy. In 800 nm wave-length, absorption coefficient of breast cancer decreased significantly after chemotherapy (before:0.0927, after;0.0498, p=0.002). Although absorption coefficient of contra-lateral normal region also decreased (before:0.0561, after;0.0437, p=0.006), cancer showed more significant decrease than contra-lateral normal region (cancer:-43.1%, normal region;-19.0%, P<0.01).
Figure 1. Absorption coefficient (pa, cm-1), at 800rim (cancer-normal)
Similar results were observed in 760 and 830 nm wave-length. There was no difference in reduced scattering coefficient (µs') between before and after chemotherapy in both breast cancer and contra-lateral normal region.
Conclusion: The absorption coefficient of cancer was significantly higher than that of contra-lateral normal region before chemotherapy and decreased significantly after chemotherapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-05-02.
Collapse
Affiliation(s)
- H Ogura
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - D Yamashita
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Nasu
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - C Teruya
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - E Ohmae
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - K Yoshimoto
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Suzuki
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Ueda
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - M Oda
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Yamashita
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H. Sakahara
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| |
Collapse
|